Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nihon Kagaku Sangyo Co., Ltd. (4094.T)
Tokyo, JP
Nihon Kagaku Sangyo Co., Ltd., a company founded in Tokyo, Japan, in 1924, specializes in the production and global distribution of a broad spectrum of industrial chemicals and construction supplies. Its chemical offerings include an extensive range of inorganic metal compounds, such as those derived from copper, tin, nickel, cobalt, bismuth, chromium, manganese, antimony, zinc, iron, and lithium. The company also manufactures organic metal compounds like metal acetylacetonate complexes, metallic soaps, PUCAT, and PA series products. Furthermore, it provides various surface treatment agents, covering anodized aluminum treatments, electroplating solutions, brighteners, additives, electroless plating agents, etchants, and rust prevention formulations. These chemicals are vital components in diverse industries, from plastics, textiles, paints, and inks to electronics, and advanced fields such as optical communications and modern battery technologies, including secondary and fuel cells. In addition to its chemical division, Nihon Kagaku Sangyo develops and supplies building materials, including fire-resistant, waterproof, and ventilation products. Its portfolio also features Cool Fin heat exchangers, stainless-steel architectural elements like handrails and mailboxes, custom-fabricated metal components for industrial applications, and specialized materials for roof eaves.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.57% | -11.50% | -15.17% | -21.53% | -7.04% | -15.59% | +6.32% | +89.55% | +71.04% | +160.63% | +597.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -2 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+10.2% ★ Q1'26: +20.7% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-3.2% Q1'26: -50.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+6.1% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+12.1% ★ Q1'26: +12.5% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+7.8% ★ Q1'26: +7.4% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
|---|---|---|---|
| Revenue |
19.84B
est: 18.87B (+5.2%)
|
22.15B
est: 19.60B (+13.0%)
|
23.96B
est: 20.40B (+17.4%)
|
| EBITDA |
3.29B
est: 3.47B (-5.2%)
|
3.56B
est: 3.61B (-1.4%)
|
3.75B
est: 3.76B (-0.2%)
|
| EBIT |
2.56B
est: 2.61B (-2.1%)
|
2.68B
est: 2.71B (-1.3%)
|
2.76B
est: 2.82B (-2.3%)
|
| Net Income |
1.82B
est: 1.70B (+7.1%)
|
1.96B
est: 1.80B (+9.0%)
|
2.35B
est: 2.01B (+16.7%)
|
| SGA |
2.13B
est: 2.11B (+1.1%)
|
2.28B
est: 2.19B (+4.0%)
|
2.30B
est: 2.28B (+0.9%)
|
| EPS |
92.08
est: 87.35 (+5.4%)
|
98.52
est: 92.60 (+6.4%)
|
117.04
est: 103.30 (+13.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akira Yamamoto | Managing Executive Officer, GM of the Corporate Planning Office & Director | — | male |
| Hiroki Kadoya | President, GM of Pharmaceutical Business Divi. & Representative Director | — | — |
| Isao Onomura | Managing Executive Officer, Deputy GM of the Chemicals Business General Headquarters | — | — |
| Osamu Matsuo | Managing Officer & GM of the Chemicals Business General Headquarters | — | — |
| Osamu Yamada | Managing Executive Officer, Deputy GM of the Chemicals Business General Headquarters | — | — |
| Sekine Toshinori | Operating Officer & GM of the Chemicals Sales Division | — | — |
| Sumitaka Watanabe | Executive Officer and GM of the R&D Center | — | — |
| Takeyuki Ohta | Senior Managing Executive Officer, GM of Administrative Hq. & Director | — | male |
| Yutaka Yoshida | Operating Officer & GM of the Corporate Planning Office | — | male |
| Yuzuru Momose | Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4094.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
